argenx Expands Partnership with Cradle for AI-Driven Protein Engineering
argenx is expanding its use of Cradle's AI-driven protein engineering platform across more discovery programs following successful initial results.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
argenx is expanding its use of Cradle's AI-driven protein engineering platform across more discovery programs following successful initial results.
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.
Piper Sandler has reaffirmed its 'Overweight' rating for argenx SE, indicating a continued positive outlook from the firm.
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.
argenx has been recognized as one of the top five large employers in the biopharmaceutical industry in BioSpace's annual 'Best Places to Work' rankings for 2027.
argenx has entered into a definitive agreement to acquire Unnatural Products, Inc. (UNP) for a total potential value of approximately $1.15 billion to advance its macrocyclic peptide discovery capabilities.